1. 023 Relapse outcomes with natalizumab Q4W vs switch to Q6W. Issue 6 (27th May 2022) Authors: Butzkueven, Helmut; Kappos, Ludwig; Spelman, Tim; Trojano, Maria; Wiendl, Heinz; Su, Ray; Hyde, Robert; Licata, Stephanie; Ho, Pei-Ran; Campbell, Nolan Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 93:Issue 6(2022) Page Start: A20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 071 Natalizumab extended interval dosing (EID) is associated with a significant reduction in progressive multifocal leukoencephalopathy (PML) risk compared with standard interval dosing (SID) in the touch® prescribing program. Issue 6 (24th May 2018) Authors: Ryerson, Lana Zhovtis; Foley, John; Chang, Ih; Kister, Ilya; Cutter, Gary; Metzger, Ryan; Goldberg, Judith D; Li, Xiaochun; Riddle, Evan; Smirnakis, Karen; Yu, Bei; Ren, Zheng; Hotermans, Christophe; Ho, Pei-Ran; Campbell, Nolan Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 89:Issue 6(2018) Page Start: A29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 085 Clinical outcomes were better for relapsing-remitting multiple sclerosis (RRMS) patients who remained on natalizumab compared to those who switched to oral or injectable therapies after 2 years in the tysabri® observational program (TOP). Issue 6 (24th May 2018) Authors: Butzkueven, Helmut; Kappos, Ludwig; Spelman, Tim; Trojano, Maria; Wiendl, Heinz; Dong, Qunming; Licata, Stephanie; Ho, Pei-Ran; Campbell, Nolan Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 89:Issue 6(2018) Page Start: A34 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 086 The rapid efficacy of natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): results from reveal, a randomised, head-to-head study. Issue 6 (24th May 2018) Authors: Butzkueven, Helmut; Jeffery, Douglas; Arnold, Douglas L; Filippi, Massimo; Geurts, Jeroen JG; Dong, Qunming; Campbell, Nolan; Licata, Stephanie; Ho, Pei-Ran Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 89:Issue 6(2018) Page Start: A35 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri® Observational Program (TOP). (March 2021) Authors: Butzkueven, Helmut; Trojano, Maria; Kappos, Ludwig; Spelman, Tim; Wiendl, Heinz; Rosales, Karen; Su, Ray; Licata, Stephanie; Ho, Pei-Ran; Campbell, Nolan Journal: Multiple sclerosis Issue: Volume 27:Number 3(2021) Page Start: 410 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Issue 5 (May 2018) Authors: Kapoor, Raju; Ho, Pei-Ran; Campbell, Nolan; Chang, Ih; Deykin, Aaron; Forrestal, Fiona; Lucas, Nisha; Yu, Bei; Arnold, Douglas L; Freedman, Mark S; Goldman, Myla D; Hartung, Hans-Peter; Havrdová, Eva Kubala; Jeffery, Douglas; Miller, Aaron; Sellebjerg, Finn; Cadavid, Diego; Mikol, Dan; Steiner, D... Journal: Lancet neurology Issue: Volume 17:Issue 5(2018) Page Start: 405 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). Issue 6 (31st March 2020) Authors: Butzkueven, Helmut; Kappos, Ludwig; Wiendl, Heinz; Trojano, Maria; Spelman, Tim; Chang, Ih; Kasliwal, Rachna; Jaitly, Seema; Campbell, Nolan; Ho, Pei-Ran; Licata, Stephanie Other Names: author non-byline.; Abraham Roby author non-byline.; Adamkova Jana author non-byline.; Airas Laura author non-byline.; Aktas Orhan author non-byline.; Albrecht Holger author non-byline.; Alsassa Roger author non-byline.; de Arcaya Esquide Amaya Alvarez author non-byline.; Angstwurm Klemens autho... Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 91:Issue 6(2020) Page Start: 660 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study. Issue 10 (20th October 2020) Authors: Butzkueven, Helmut; Licata, Stephanie; Jeffery, Douglas; Arnold, Douglas L; Filippi, Massimo; Geurts, Jeroen JG; Santra, Sourav; Campbell, Nolan; Ho, Pei-Ran Journal: BMJ open Issue: Volume 10:Issue 10(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study. Issue 10 (20th October 2020) Authors: Butzkueven, Helmut; Licata, Stephanie; Jeffery, Douglas; Arnold, Douglas L; Filippi, Massimo; Geurts, Jeroen JG; Santra, Sourav; Campbell, Nolan; Ho, Pei-Ran Journal: BMJ open Issue: Volume 10:Issue 10(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study. Issue 10 (20th October 2020) Authors: Butzkueven, Helmut; Licata, Stephanie; Jeffery, Douglas; Arnold, Douglas L; Filippi, Massimo; Geurts, Jeroen JG; Santra, Sourav; Campbell, Nolan; Ho, Pei-Ran Journal: BMJ open Issue: Volume 10:Issue 10(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗